Chiesi’s new licensing deal with Haisco; Oxurion to file for bankruptcy; Hong Kong CDMO raises $210M
Chiesi, Haisco to develop respiratory treatment outside of China: The companies said Monday that they plan to work together to develop, manufacture and potentially commercialize a reversible dipeptidyl peptidase 1 inhibitor outside of China, Hong Kong, Macau and Taiwan. Financial terms of the deal were not disclosed. Haisco is currently testing the therapy in Phase II studies in China for bronchiectasis, a condition that causes a buildup of mucus in the lungs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.